The effects of zinc supplementation in the treatment of patients with brucellosis

The effects of zinc supplementation on clinical status, inflammatory factors, and oxidative stress biomarkers in patients with brucellosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N70

Enrollment

Registered

2020-04-19

Start date

2019-03-07

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis. Brucellosis

Interventions

Intervention 1: Intervention group: 30 mg elemental zinc (Donyayeh Behdasht, Tehran, Iran) daily for 8 weeks orally. Intervention 2: Control group: Placebo (Donyayeh Behdasht, Tehran, Iran), daily for

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with brucellosis Individuals aged 18-80 years

Exclusion criteria

Exclusion criteria: Taking any antioxidant and/or anti-inflammatory supplements within 3 months prior to the enrollment. Patients diagnosed with acquired immunosuppressive disease Patients who are receiving any immunosuppressive drugs.

Design outcomes

Primary

Measure	Time frame
Serum hs-CRP levels. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa.	—

Secondary

Measure	Time frame
Fever duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Chills duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Sweating duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Arthritis duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Arthralgia duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: After intervention.;Myalgia duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Anorexia duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Fever duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Chills duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Sweating duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Arthritis duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Arthralgia duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: After intervention.;Myalgia duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Anorexia duration. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Checklist.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hamid Niaparast

Kashan University of Medical Sciences

niaparast.h@gmail.com+98 31 5562 0608

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026